The effects of IL-2, IL-6 and IL-10 levels on prognosis in patients with aggressive Non-Hodgkin's Lymphoma (NHL)

Journal of Experimental and Clinical Cancer Research

Volumn 23, Issue 3, 2004, Pages 485-488

  Ozdemir, Feyyaz ^a   Aydin, F ^a   Yilmaz, M ^a   Kavgaci, H ^a   Bektas, O ^a   Yavuz, M N ^a   Yavuz, A A ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

IL 10; IL 2; IL 6; Non Hodgkin's Lymphoma

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; METHYLPREDNISOLONE; PREDNISONE; VINCRISTINE;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNE SYSTEM; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TREATMENT FAILURE; TUMOR GROWTH;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOXORUBICIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-6; LYMPHOMA; LYMPHOMA, NON-HODGKIN; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PREDNISONE; PROGNOSIS; REGRESSION ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; VINCRISTINE;

EID: 8544247939     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Armitage J.O., Mauch P.M., Harris N.L., Bierman P.: Non-Hodgkin's Lymphomas. In: De Vita V.T. Jr., Hellman S., Rosenberg S.A.,eds. Cancer Principles and Practice of Oncology. Philadelphia: Lippincott Williams and Wilkins 2236-2316, 2001.
2. Shipp M., Harrington D., Anderson J., et al.: A predictive model for aggressive non-Hodgkin's lymphoma: The international non-Hodgkin's lymphoma prognostic factors Project. N Engl. J. Med. 329:987-994, 1993.
3. Aydin R, Ulusoy S., Ovali E.: Results of treatment with cyclophosphamid, doxorubicine, vincristine, and prednisone (CHOP) for non-Hodgkin's aggressive lymphoma analyzed according to the international prognostic index. J. Chemother. 9:446-451, 1997.
4. Cortes I.E., Talpaz M., Cabanillas F., et al.: Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: Lack of correlation with prognosis. Blood 85:2516-20, 1995.
5. Hsu S.M., Waldron J.W. Jr., Hsu P.L., et al.: Cytokines in malignant lymphomas: view and prospective evaluation. Hum. Pathol. 24:1040-1057, 1993.
6. Pretti H.A., Cabanillas F., Talpaz M., et al.: Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann. Intern. Med. 127:1861-94, 1997.
7. Stasi R., Zinzani P.L., Galieni P., et al.: Clinical implications of cytokines and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma. Eur. J. Haematol. 54:9-17, 1995.
8. Aydih F., Yilmaz M., Ozdemir F., et al.: Correlation of serum IL-2, IL-6 and IL-10 levels with International Prognostic Index in patients with aggressive non-Hodgkin's lymphoma. Am. J. Clin. Oncol. 25:570-572, 2002.
9. Stasi R., Zinzani P.L., Galieni P., et al.: Prognostic value of interleukiri-10 and soluble interleukin-2 receptor levels in aggressive non-Hodgkin's lymphoma. Br. J. Haematol. 88:770-777, 1994.
10. Blay J.Y., Burdin N., Prosset R, et al.: Serum interleukin-10 in non-Hodgkin's lymphoma: A prognostic factor. Blood 82:2169-2174, 1993.
11. Cortes J., Kurzrock R.: Interleukin-10 in non-Hodgkin's lymphoma. Leuk. Lymphoma 26:251-259, 1997.
12. Seymour J.F., Talpaz M., Cabanillas F., et al.: Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J. Clin. Oncol. 13:373-382, 1995.
13. Betay R.M., Rulli K., Bost K.L., et al.: High levels of interleukin-4 and interleukin-10 mRNA and low levels of interleukin-2, interleukin-9 and gamma interferon mRNA in muIV-induced lymphomas. Virology 261:253-262, 1999.
14. Kato H., Kinoshita T., Suzuki S., et al.: Production and effects of interleukin-6 and other cytokines in patients with non-Hodgkin's lymphoma. Leuk. Lymphoma 29:71-79, 1997.
15. Pui C.H., Ip S.H., Kung P., et al.: High serum interleukin-2 receptor levels are related to advanced disease and a poor outcome in childhood non Hodgkin's lymphoma. Blood 70:624-628, 1987.